Understanding the Development, Standardization, and Validation Process of Alternative In Vitro Test Methods for Regulatory Approval from a Researcher Perspective
Open accessAbstract
Due to economic, practical, ethical, and scientific reasons, researchers, among others, are pushing for alternative in vitro test methods to replace or reduce existing animal experiments. In order for these tests to be more broadly used by the industrial sector and regulatory bodies, orchestrated efforts are required to show the robustness and reliability of in vitro methods, which can accelerate the use for early screening testing. Another way of increasing the use of alternatives is to coordinate validation studies, that is, multi‐laboratory trials, and to gain regulatory approval and instatement as test guidelines or standard method. However, awareness of the exact standardization, validation, and approval process has been a major obstacle for many researchers. Herein, the process has been broken down into three main phases: i) test method development; ii) intra‐ and inter‐laboratory validation; and iii) regulatory acceptance. This general process applies to all alternative methods seeking validation and approval, although the intricacies of different toxicological endpoints and/or chemical sectors may lead to additional work, particularly in the validation stage. The authors’ aim is to provide insight in the development process of alternative methods with a focus on in vitro cell culture methods over validation to regulatory acceptance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Data reviewers, e.g., companies and regulatory agencies responsible for product registrations, will have increased confidence in data generated in laboratories adhering to GIVIMP standards.
“Also, data reviewers, e.g., companies and regulatory agencies responsible for product registrations, will have increased confidence in data generated in laboratories adhering to GIVIMP standards (Bas et al., 2021).”
From How a GIVIMP certification program can increase confidence in in vitro methods (2021) · cites this paper as Bas et al., 2021
Section 2.1.1 (The OECD; page unavailable) says GIVIMP provides practices for laboratories generating test data and aims to reduce uncertainty in in vitro predictions. That supports the rationale for greater confidence, but the paper does not say that companies or regulatory agencies reviewing product registrations will have increased confidence in data from GIVIMP-adherent laboratories. (LLM, conf=0.81)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300313 · Cited by 371 · see citing works
Guidance Document on Good In Vitro Method Practices (GIVIMP)
OECD (2018) · OECD Series on Testing and Assessment · doi:10.1787/9789264304796-en · Cited by 161 · see citing works
https://www.altex.org/index.php/altex/article/view/1339
Krebs, A., Waldmann, T., Wilks, M. F., van Vugt-Lussenburg, B. M. A., van der Burg, B., Terron, A., Steger-Hartmann, T., Ruegg, J., Rovida, C., Pedersen, E., et al. (2019) · ALTEX · doi:10.14573/altex.1909271 · Cited by 77 · see citing works
Flagged first, then by citations
Research works printed but not linked: 58
- E. Walum, J. Hedander, P. Garberg, Toxicol. Appl. Pharmacol. 2005, 207, 393.
- A. Bal-Price, H. T. Hogberg, K. M. Crofton, M. Daneshian, R. E. FitzGerald, E. Fritsche, T. Heinonen, S. Hougaard Ben- nekou, S. Klima, A. H. Piersma, M. Sachana, T. J. Shafer, A. Terron, F. Monnet-Tschudi, B. Viviani, T. Waldmann, R. H. S. Westerink, M. F. Wilks, H. Witters, M. G. Zurich, M. Leist, Altex 2018, 35, 306.
- J. Draize, G. Woodard, H. Calvery, J. Pharmacol. Exp. Ther. 1944, 82, 377.
- M. York, W. Steiling, J. Appl. Toxicol. 1998, 18, 233.
- D. Basketter, D. Jirova, H. Kandarova, Interdiscip. Toxicol. 2012, 5, 98.
- M. Lee, J. H. Hwang, K. M. Lim, Toxicol. Res. 2017, 33, 191.
- M. Leist, T. Hartung, Arch. Toxicol. 2013, 87, 563.
- H. R. Ferdowsian, N. Beck, PLoS One 2011, 6, e24059.
- I. A. Freires, J. C. Sardi, R. D. de Castro, P. L. Rosalen, Pharm. Res. 2017, 34, 681.
- H. Raunio, Front. Pharmacol. 2011, 2, 33.
- N. Alepee, A. Bahinski, M. Daneshian, W. B. De, E. Fritsche, A. Goldberg, J. Hansmann, T. Hartung, J. Haycock, H. Hogberg, L. Hoelting, J. M. Kelm, S. Kadereit, E. McVey, R. Landsiedel, M. Leist, M. Lubberstedt, F. Noor, C. Pellevoisin, D. Petersohn, U. Pfannenbecker, K. Reisinger, T. Ramirez, B. Rothen-Rutishauser, M. Schafer-Korting, K. Zeilinger, M. G. Zurich, Altex 2014, 31, 441.
- R. F. Luder, M. Buettner, A. Bleich, Altex 2019, 36, 141.
- S. Gordon, M. Daneshian, J. Bouwstra, F. Caloni, S. Constant, D. E. Davies, G. Dandekar, C. A. Guzman, E. Fabian, E. Haltner, T. Hartung, N. Hasiwa, P. Hayden, H. Kandarova, S. Khare, H. F. Krug, C. Kneuer, M. Leist, G. Lian, U. Marx, M. Metzger, K. Ott, P. Prieto, M. S. Roberts, E. L. Roggen, T. Tralau, C. van den Braak, H. Walles, C. M. Lehr, Altex 2015, 32, 327.
- K. Jaroch, A. Jaroch, B. Bojko, J. Pharm. Biomed. Anal. 2018, 147, 297.
- J. Zavala, A. N. Freedman, J. T. Szilagyi, I. Jaspers, J. F. Wambaugh, M. Higuchi, J. E. Rager, Int. J. Environ. Res. Public Health 2020, 17, 2124.
- A. Kinsner-Ovaskainen, G. Maxwell, J. Kreysa, J. Barroso, E. Adriaens, N. Alepee, N. Berg, S. Bremer, S. Coecke, J. Z. Comenges, R. Corvi, S. Casati, N. G. Dal, M. Marrec-Fairley, C. Griesinger, M. Halder, E. Heisler, D. Hirmann, A. Kleensang, A. Kopp-Schneider, S. Lapenna, S. Munn, P. Prieto, L. Schechtman, T. Schultz, J. M. Vidal, A. Worth, V. Zuang, ATLA, Altern. Lab. Anim. 2012, 40, 175.
- C. Rovida, N. Alepee, A. M. Api, D. A. Basketter, F. Y. Bois, F. Caloni, E. Corsini, M. Daneshian, C. Eskes, J. Ezendam, H. Fuchs, P. Hayden, C. Hegele-Hartung, S. Hoffmann, B. Hubesch, M. N. Jacobs, J. Jaworska, A. Kleensang, N. Kleinstreuer, J. Lalko, R. Landsiedel, F. Lebreux, T. Luechtefeld, M. Locatelli, A. Mehling, A. Natsch, J. W. Pitchford, D. Prater, P. Prieto, A. Schepky, et al., Altex 2015, 32, 25.
- S. Halappanavar, S. van den Brule, P. Nymark, L. Gate, C. Seidel, S. Valentino, V. Zhernovkov, P. Hogh Danielsen, A. De Vizcaya, H. Wolff, T. Stoger, A. Boyadziev, S. S. Poulsen, J. B. Sorli, U. Vogel, Part. Fibre Toxicol. 2020, 17, 16.
- H. Barosova, A. G. Maione, D. Septiadi, M. Sharma, L. Haeni, S. Balog, O. O'Connell, G. R. Jackson, D. Brown, A. J. Clippinger, P. Hayden, A. Petri-Fink, V. Stone, B. Rothen-Rutishauser, ACS Nano 2020, 14, 3941.
- European Union, Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the Protection of Animals Used for Scientific Purposes, in Official Journal of the European Union 2010.
- J. E. Doe, A. R. Boobis, A. Blacker, V. Dellarco, N. G. Doerrer, C. Franklin, J. I. Goodman, J. M. Kronenberg, R. Lewis, E. E. McConnell, T. Mercier, A. Moretto, C. Nolan, S. Padilla, W. Phang, R. Solecki, L. Tilbury, B. van Ravenzwaay, D. C. Wolf, Crit. Rev. Toxicol. 2006, 36, 37.
- S. Fox, S. Farr-Jones, L. Sopchak, A. Boggs, H. W. Nicely, R. Khoury, M. Biros, J. Biomol. Screen. 2006, 11, 864.
- T. Hartung, E. van Vliet, J. Jaworska, L. Bonilla, N. Skinner, R. Thomas, Altex 2012, 29, 119.
- W. Lilienblum, W. Dekant, H. Foth, T. Gebel, J. G. Hengstler, R. Kahl, P. J. Kramer, H. Schweinfurth, K. M. Wollin, Arch. Toxicol. 2008, 82, 211.
- T. Hartung, Altex 2007, 24, 67.
- I. A. S. Olsson, S. P. D. Silva, D. Townend, P. Sandoe, ILAR J. 2016, 57, 347.
- H. Kandarova, S. Letasiova, Interdiscip.Toxicol. 2011, 4, 107.
- S. Coecke, M. Balls, G. Bowe, J. Davis, G. Gstraunthaler, T. Hartung, R. Hay, O. W. Merten, A. Price, L. Schechtman, G. Stacey, W. Stokes, ATLA, Altern. Lab. Anim. 2005, 33, 261.
- J. M. Wiggins, J. A. Albanese, Monograph Development: Why and When to Participate in BioPharm International, Vol. 2020, 2020.
- M. R. Nepal, T. C. Jeong, Biomol. Ther. 2020, 28, 302.
- K. Taylor, C. Gericke, L. R. Alvarez, Altex 2019, 36, 81.
- K. B. Bayne, D. A. C. Bayvel, V. Williams, Laboratory Animal Welfare: International Issues, in Laboratory Animal Welfare (Eds: K. Bayne, P.V. Turner), Elsevier, Amsterdam 2014.
- S. Beken, P. Kasper, J. W. van der Laan, Adv. Exp. Med. Biol. 2016, 856, 33.
- C. Lourenco, N. Orphanos, C. Parker, Pharm. Policy Law 2016, 18, 79.
- C. Griesinger, B. Desprez, S. Coecke, W. Casey, V. Zuang, Adv. Exp. Med. Biol. 2016, 856, 65.
- A. A. Bottini, P. Amcoff, T. Hartung, Altex 2007, 24, 255.
- W. S. Stokes, L. M. Schechtman, R. N. Hill, ATLA, Altern. Lab. Anim. 2002, 30, 23.
- M. Nakamura, T. Haarmann-Stemmann, J. Krutmann, A. Morita, Exp. Dermatol. 2018, 27, 495.
- C. S. Pridgeon, C. Schlott, M. W. Wong, M. B. Heringa, T. Heckel, J. Leedale, L. Launay, V. Gryshkova, S. Przyborski, R. N. Bearon, E. L. Wilkinson, T. Ansari, J. Greenman, D. F. G. Hendriks, S. Gibbs, J. Sidaway, R. L. Sison-Young, P. Walker, M. J. Cross, B. K. Park, C. E. P. Goldring, Arch. Toxicol. 2018, 92, 557.
- S. Bitz, Altex 2010, 27, 114.
- M. Whelan, C. Eskes, Adv. Exp. Med. Biol. 2016, 856, 387.
- National Research Council, Intentional Human Dosing Studies for EPA Regulatory Purposes: Scientific and Ethical Issues, The National Academies Press, Washington, DC 2004, p. 226.
- C. D. B. Griesinger, S. Coecke, W. Casey, V. Zuang, Validation of Alternative In Vitro Methods in the Development and Approval of Pharmaceuticals in Validation of Alternative Methods for Toxicity Testing (Eds: M. Whelan, C. Eskes), Springer International Publishing, Switzerland 2016.
- W. Stokes, Validation and Regulatory Acceptance of Toxicological Testing Methods and Strategies in Principles and Methods of Toxicology, 6th ed. (Eds: A. W. Hayes, C. L. Kruger), CRC Press, Boca Raton, FL 2014.
- T. Hartung, S. Bremer, S. Casati, S. Coecke, R. Corvi, S. Fortaner, L. Gribaldo, M. Halder, S. Hoffmann, A. J. Roi, P. Prieto, E. Sabbioni, L. Scott, A. Worth, V. Zuang, ATLA, Altern. Lab. Anim. 2004, 32, 467.
- F. P. Gruber, T. Hartung, Altex 2004, 21, 3.
- D. Pamies, A. Bal-Price, A. Simeonov, D. Tagle, D. Allen, D. Gerhold, D. Yin, F. Pistollato, T. Inutsuka, K. Sullivan, G. Stacey, H. Salem, M. Leist, M. Daneshian, M. C. Vemuri, R. McFarland, S. Coecke, S. C. Fitzpatrick, U. Lakshmipathy, A. Mack, W. B. Wang, D. Yamazaki, Y. Sekino, Y. Kanda, L. Smirnova, T. Hartung, Altex 2017, 34, 95.
- D. Pamies, A. Bal-Price, C. Chesne, S. Coecke, A. Dinnyes, C. Eskes, R. Grillari, G. Gstraunthaler, T. Hartung, P. Jennings, M. Leist, U. Martin, R. Passier, J. C. Schwamborn, G. N. Stacey, H. Ellinger-Ziegelbauer, M. Daneshian, Altex 2018, 35, 353.
- R. S. Judson, R. S. Thomas, N. Baker, A. Simha, X. M. Howey, C. Marable, N. C. Kleinstreuer, K. A. Houck, Altex 2019, 36, 261.
- A. Krebs, T. Waldmann, M. F. Wilks, B. M. A. Van Vugt- Lussenburg, B. Van der Burg, A. Terron, T. Steger-Hartmann, J. Ruegg, C. Rovida, E. Pedersen, G. Pallocca, M. Luijten, S. B. Leite, S. Kustermann, H. Kamp, J. Hoeng, P. Hewitt, M. Herzler, J. G. Hengstler, T. Heinonen, T. Hartung, B. Hardy, F. Gantner, E. Fritsche, K. Fant, J. Ezendam, T. Exner, T. Dunkern, D. R. Dietrich, S. Coecke, et al., Altex 2019, 36, 682.
- R. Osborne, M. A. Perkins, Toxicol. In Vitro 1991, 5, 563.
- H. Spielmann, S. Hoffmann, M. Liebsch, P. Botham, J. H. Fentem, C. Eskes, R. Roguet, J. Cotovio, T. Cole, A. Worth, J. Heylings, P. Jones, C. Robles, H. Kandarova, A. Gamer, M. Remmele, R. Curren, H. Raabe, A. Cockshott, I. Gerner, V. Zuang, ATLA, Altern. Lab. Anim. 2007, 35, 559.
- D. De Wever, D. Petersohn, K. R. Mewes, Household Pers. Care Today 2013, 8, 18.
- M. Faria, M. Bjornmalm, K. J. Thurecht, S. J. Kent, R. G. Parton, M. Kavallaris, A. P. R. Johnston, J. J. Gooding, S. R. Corrie, B. J. Boyd, P. Thordarson, A. K. Whittaker, M. M. Stevens, C. A. Prestidge, C. J. H. Porter, W. J. Parak, T. P. Davis, E. J. Crampin, F. Caruso, Nat. Nanotechnol. 2018, 13, 777.
- K. Rasmussen, H. Rauscher, P. Kearns, M. Gonzalez, J. Riego Sintes, Regul. Toxicol. Pharmacol. 2019, 104, 74.
- K. G. Steinhäuser, P. G. Sayre, NanoImpact 2017, 7, 66.
- K. Taylor, Altex 2014, 31, 215.
- F. Sewell, J. Doe, N. Gellatly, I. Ragan, N. Burden, Regul. Toxicol. Pharmacol. 2017, 89, 50.
Cited by
Sorted by citations
Portugal-Cohen, M., Cohen, D., Kohen, R., & Oron, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1215266 · Cited by 24 · see citing works
How a GIVIMP certification program can increase confidence in in vitro methods
Ulrey, A. (2021) · ALTEX · doi:10.14573/altex.2102261 · Cited by 17 · see citing works
Brizio, M., Mancini, M., Lora, M., Joy, S., Zhu, S., Brilland, B., Reinhardt, D. P., Farge, D., Langlais, D., & Colmegna, I. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03916-9 · Cited by 13 · see citing works
Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells
Pistollato, F., Bal-Price, A., Coecke, S., Parvatam, S., Pamies, D., Czysz, K., Hao, J., Kee, K., Teo, A. K. K., Niu, S., et al. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.06.003 · Cited by 10 · see citing works
- Authors
- Bas, A., Burns, N., Gulotta, A., Junker, J., Drasler, B., Lehner, R., Aicher, L., Constant, S., Petri‐Fink, A., & Rothen‐Rutishauser, B.
- Affiliations
- Worcester Polytechnic Institute (US)
- Adolphe Merkle Institute University of Fribourg Fribourg 1700 Switzerland
- University of Fribourg (CH)
- University of Basel (CH)
- Epithelix Sàrl Plan‐Les‐Ouates Geneva 1228 Switzerland
- Corresponding author
- Rothen‐Rutishauser, Barbara
- Venue
- Small
- Publisher
- Wiley
- Published
- 2021-01-22
- Volume
- 17
- Issue
- 15
- Pages
- e2006027-e2006027
- ISSN
- 1613-6810 (ISSN-L)
- 1613-6829
- OpenAlex
- W3123859057
- Cited by
- 60
- References
- 3
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 3
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Small (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Adolphe Merkle Foundation
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- 3Rs, animal testing reduction, test method development, interlaboratory validation, regulatory acceptance, standardization, in vitro cell culture, toxicity screening, test guidelines
- MeSH terms
- Animals, Animal Testing Alternatives, Reference Standards, Reproducibility of Results, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review